Evolution of Antiemetic Treatment in Hematologic Patients

References

• Canevari A., Pagnucco G., Castelli Bonfichi G. M., Santagostino A., Bernasconi C. The antiemetic therapy in antineoplastic chemotherapy. “Attualità di chemioterapia antineoplastica in Ematologia”, C. Bernasconi. EMP Publishers, Pavia 1987; 259–66
   Google Scholar
• Borison H. L., McCarthy L. E. Neuropharmacology of chemotherapy induced emesis. Drugs 1983; 25: 8
   PubMed Web of Science ®Google Scholar
• Laszlo J. Nausea and vomiting as major complications of Cancer chemotherapy. Drugs 1983; 25(Suppl. 1)1
   PubMed Web of Science ®Google Scholar
• Bakowski M. T. Advances in anti-emetic therapy. Cancer Treatment Reviews 1984; 11: 237
   PubMed Web of Science ®Google Scholar
• Peroutka S. J., Snyder S. H. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. The Lancet 1982; 20: 658
   Google Scholar
• Pollera C. F., Giannarelli D. Prognostic factors influencing cis-platin induced emesis. Cancer 1989; 64: 1117
   PubMed Web of Science ®Google Scholar
• Roila F., Tonato M., Basurto C. Antiemetic activity of high doses of metoclopramide combined with methyl-prednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1987; 5: 141
   PubMed Web of Science ®Google Scholar
• Depierre A., Lebeau B., D'Allens French H., Pneumology Group for Ondansetron Study. Comparison of ondansetron with a combined regimen of alizapride and methyl-prednisolone in the prophylaxis of cisplatin-induced emesis in patient with lung cancer. Proceedings of the 3rd International Congress of Neo-adjuvant chemotherapy, Ondansetron and Chemotherapy induced emesis, Paris, Glaxo, 1991
   Google Scholar
• Droz J. P., Lane-Allman E. Effective emesis control with ondansetron in cisplatin treated patients refractory to routinely used anti-emetics. European Journal of Cancer 1991, Suppl. 2: S293
   Google Scholar
• Tonato M., Roila F. Antiemetics Drugs. “Medical Oncologic Therapy”, A. Santoro, G. Bonadonna. Napoli, S.E.S. Publishers. 1990; 133–48
   Google Scholar
• Clark R. A., Gralla R. J., Kris M. G., et al. Exploring very high doses of metoclopramide (4–6mg/kg): Preservation of efficacy and safety with only a single dose in a combination antiemetic regimen. Proc Am Soc Clin Oncol 1989; 8: 330
   Google Scholar
• Kris M. G., Gralla R. J., Tyson L. B., et al. Controlling delayed vomiting: double blind randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Gisselbrecht C., Paillarse J. M., French Haematology Group for the study of Ondansetron (1991) . Comparison of ondansetron and alizapride in the prophylaxis of lymphoma chemotherapy induced emesis. Proceedings of 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 52
   Google Scholar
• Basurto C, Roila F., De Favero A., et al. A prospective randomized double-blind cross-over study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy. Cancer Invest 1988; 6: 475
   PubMed Web of Science ®Google Scholar
• Joss R. A., Galeazzi R. L., Bischoff A. K., et al. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Clin Pharmacol Ther 1986; 39: 619
   PubMed Web of Science ®Google Scholar
• Sailer R., Hellenbrecht D. Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and aliza pride, against cisplatin-induced emesis. Cancer Treat Rep 1985; 69: 1301
   PubMedGoogle Scholar
• Kris M. G., Gralla R. J., Clark R. A., et al. -Anti-emetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 1987; 60: 2816
   PubMed Web of Science ®Google Scholar
• Tyers M. B., Bunce K. T., Humphrey P. P. A. Pharmacological and anti-emetic properties of ondansetron. Eur J Cancer Clin Oncol 1989; 25(Suppl. 1)15
   PubMedGoogle Scholar
• Campora E., Merlini L., Giudici S., et al (1991) Randomized trial of ondansetron and dexamethasone versus metoclopramide, dexamethasone and orphenadrine for the control of acute and delayed FEC-FAC induced emesis. Proceedings of 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 55
   Google Scholar
• Dicato M., Ries F., Steffen M. J., Thoma L. (1991) Ondansetron is highly efficient in preventing acute emesis in high dose 4-epirubicin therapy. Proceedings of 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 56
   Google Scholar
• Soukop M. (1991) Control of emesis and quality of life during multiple-cycles chemotherapy in the treatment of breast cancer. Proceedings of the 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 29–37
   Google Scholar
• Jiigens H., Europea paediatric Emesis Study Group (1991) . Ondansetron as prophylaxis for chemotherapy-and radiotherapy-induced emesis in children. Proceedings of the 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 21–25
   Google Scholar
• Bosi A., Guidi S., Saccardi R., et al (1991) Antiemetic prophylaxis with Ondansetron in BMT. proceedings of the 33rd Congress of the Italian Society of Hematology, Verona, 1991, 14
   Google Scholar